Alaunos Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TCRT Nasdaq 2836 www.alaunos.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alaunos Therapeutics, Inc.

Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers - May 26th, 2026 12:05 pm
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies - May 26th, 2026 9:01 am
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models - May 18th, 2026 6:00 am
Valion Bio Appoints Melinda Lackey as General Counsel - May 4th, 2026 2:05 pm
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders - Mar 2nd, 2026 4:30 am
Ziopharm: Q3 Earnings Snapshot - Nov 14th, 2025 2:31 pm
Ziopharm: Q2 Earnings Snapshot - Aug 14th, 2025 4:56 pm
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Jun 23rd, 2025 6:00 am